TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)

Jean-Luc Bodmer; Kim Burns; Pascal Schneider; Kay Hofmann; Véronique Steiner; Margot Thome; Thierry Bornand; Michael Hahne; Michael Schröter; Karin Becker; Anne Wilson; Lars E. French; Jeffrey L. Browning; H.Robson MacDonald; Jürg Tschopp

doi:10.1016/S1074-7613(00)80244-7

Retour

TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)

Article de revue

Avec comité de lecture

TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)

Jean-Luc Bodmer, Kim Burns, Pascal Schneider, Kay Hofmann, Véronique Steiner, Margot Thome, Thierry Bornand, Michael Hahne, Michael Schröter, Karin Becker, …

Immunity (Cambridge, Mass.), Vol.6(1), pp.79-88

1997

DOI: https://doi.org/10.1016/S1074-7613(00)80244-7

PMID: 9052839

Résumé

A novel member of the tumor necrosis factor (TNF) receptor family, designated TRAMP, has been identified. The structural organization of the 393 amino acid long human TRAMP is most homologous to TNF receptor 1. TRAMP is abundantly expressed on thymocytes and lymphocytes. Its extracellular domain is composed of four cysteine-rich domains, and the cytoplasmic region contains a death domain known to signal apoptosis. Overexpression of TRAMP leads to two major responses, NF-κB activation and apoptosis. TRAMP-induced cell death is inhibited by an inhibitor of ICE-like proteases, but not by Bcl-2. In addition, TRAMP does not appear to interact with any of the known apoptosis-inducing ligands of the TNF family.

Indicateurs

1 Consultations de la notice

Détails

Titre: TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)
Créateurs - sans rôle: Jean-Luc Bodmer - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Kim Burns - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Pascal Schneider - University of Lausanne
Kay Hofmann - Swiss Institute for Experimental Cancer Research, BIL Research Center, Chemin des Boveresses 155, CH-1066, Epalinges, Switzerland
Véronique Steiner - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Margot Thome - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Thierry Bornand - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Michael Hahne - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Michael Schröter - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Karin Becker - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Anne Wilson - Ludwig Institute of Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, USA
Lars E. French - Department of Dermatology, University of Geneva Medical School, CH-1211, Geneva, 4, Switzerland
Jeffrey L. Browning - Biogen, Inc., Department of Immunology and Inflammation, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA
H.Robson MacDonald - Ludwig Institute of Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, USA
Jürg Tschopp - Institute of Biochemistry, Lausanne Branch, University of Lausanne, Lausanne, USA
Détails de publication: Immunity (Cambridge, Mass.), Vol.6(1), pp.79-88
Éditeur: Elsevier Inc
Nombre de pages: 10
Identifiants: 99153915409311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article